DA
BIO icon

Duality Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Duality Advisers’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,258
Closed -$435K – 67
2024
Q1 		$435K Sell
1,258
-7,306
-85% -$2.4M 0.04% 463
2023
Q4 		$2.77M Buy
8,564
+6,953
+432% +$2.18M 0.29% 112
2023
Q3 		$577K Sell
1,611
-5,463
-77% -$2.11M 0.07% 390
2023
Q2 		$2.68M Buy
7,074
+6,656
+1,592% +$2.71M 0.34% 98
2023
Q1 		$200K Buy
+418
New +$196K 0.02% 517
2022
Q4 		– Sell
-9,003
Closed -$3.76M – 595
2022
Q3 		$3.76M Buy
+9,003
New +$4.49M 0.41% 64
2022
Q2 		– Sell
-9,349
Closed -$5.27M – 610
2022
Q1 		$5.27M Buy
+9,349
New +$5.64M 0.57% 17

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Duality Advisers's BIO Position: Q2 2024 in Review

Duality Advisers sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 1,258 shares — an estimated $435K sold.

Duality Advisers first reported a position in BIO in Q1 2022 and held it in 7 quarters. The position peaked at $5.27M in Q1 2022. 439 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Duality Advisers reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 1,258 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $435K.
  • Duality Advisers first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 7 quarters.
  • Duality Advisers's Bio-Rad Laboratories Class A position peaked at $5.27M in Q1 2022.
  • 439 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.